Xenetic Biosciences, Inc. (XBIO)
NASDAQ: XBIO · Real-Time Price · USD
2.990
-0.140 (-4.47%)
At close: Mar 24, 2026, 4:00 PM EDT
3.120
+0.130 (4.35%)
After-hours: Mar 24, 2026, 5:44 PM EDT

Xenetic Biosciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
2.982.52.541.711.16
Revenue Growth (YoY)
19.04%-1.56%48.80%47.06%165.64%
Selling, General & Admin
2.753.423.563.653.74
Research & Development
3.073.293.494.773.16
Total Operating Expenses
5.816.77.068.426.91
Operating Income
-2.83-4.2-4.52-6.72-5.75
Interest Income
0.150.250.360.170.1
Other Non-Operating Income (Expense)
0.160.240.410.160.1
Total Non-Operating Income (Expense)
0.310.490.760.330.2
Pretax Income
-2.53-3.72-3.75-6.39-5.54
Net Income
-2.68-3.96-4.13-6.55-5.65
Net Income to Common
-2.68-3.96-4.13-6.55-5.65
Shares Outstanding (Basic)
22211
Shares Outstanding (Diluted)
22211
Shares Change (YoY)
10.40%0.86%7.44%38.38%60.81%
EPS (Basic)
-1.58-2.57-2.71-4.61-5.50
EPS (Diluted)
-1.58-2.57-2.71-4.61-5.50
Free Cash Flow
-2.29-2.82-4.11-4.65-4.74
Free Cash Flow Per Share
-1.34-1.83-2.69-3.27-4.61
Gross Margin
100.00%100.00%100.00%100.00%100.00%
Operating Margin
-95.23%-168.16%-177.79%-393.57%-495.12%
Profit Margin
-90.07%-158.39%-162.78%-383.87%-486.36%
FCF Margin
-76.83%-112.69%-161.98%-272.23%-408.21%
EBITDA
-2.83-4.2-4.52-6.69-5.71
EBITDA Margin
-95.23%-168.16%-177.79%-391.98%-492.06%
EBIT
-2.83-4.2-4.52-6.72-5.75
EBIT Margin
-95.23%-168.16%-177.79%-393.57%-495.12%
Updated Mar 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q